Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Malignant Disease × Carboplatin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 107 Ovarian Neoplasms 63 Neoplasms 61 Fallopian Tube Neoplasms 40 Lung Neoplasms 37 Breast Neoplasms 32 Carcinoma, Ovarian Epithelial 25 Neoplasm Metastasis 24 Triple Negative Breast Neoplasms 19 Small Cell Lung Carcinoma 19 Esophageal Neoplasms 19 Endometrial Neoplasms 18 Colorectal Neoplasms 15 Advanced Solid Tumors 14 Squamous Cell Carcinoma of Head and Neck 13 Lymphoma, Large B-Cell, Diffuse 13 Unspecified Adult Solid Tumor, Protocol Specific 12 Stomach Neoplasms 11 Melanoma 11 Central Nervous System Neoplasms 11 Uterine Cervical Neoplasms 10 Pancreatic Neoplasms 10 Astrocytoma 10 Neuroblastoma 9 Medulloblastoma 9 Head and Neck Neoplasms 9 Carcinoma 9 Urinary Bladder Neoplasms 8 Solid Tumors 8 Precursor Cell Lymphoblastic Leukemia-Lymphoma 8

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡